BPC-157 side effects: what the studies report

Is BPC-157 safe, and what side effects have studies reported?

The FDA's July 2026 review judged the clinical safety information on BPC-157 insufficient to characterise its profile. In its July 2026 briefing document, the FDA listed five small human studies of 2 to 53 people each, saw no serious adverse events appear to have been reported in them, and noted their short duration, small samples and limited safety data (FDA, July 2026). The commonest minor events in the healthy-volunteer abstracts, which covered 32 male volunteers (24 given BPC-157) and are abstracts only, were headache and flatulence, and they happened about as often on placebo (Veljaca et al., meeting abstracts, 2002 and 2003, as tabulated by the FDA). A quiet record is not a clean record.

Why does a record with no reported problems still count as unfinished? Such small studies cannot reliably estimate event rates or rule out uncommon harms. A 2025 review of those three pilots, a 17-chart knee review with 16 patients contacted, a bladder pilot in 12 women and a pilot in two adults, reported no adverse effects, but these small uncontrolled studies cannot establish safety (McGuire et al., Current Reviews in Musculoskeletal Medicine, 2025). You can read more about the compound itself in the BPC-157 research guide.

That gap also answers the many questions about how long exposure lasts. The FDA's list of five human studies records repeated exposure for two weeks at most, in meeting-abstract studies of 32 healthy volunteers and 53 adults with ulcerative colitis, abstracts with incomplete methods and limited safety reporting, and the review calls the information on long-term use insufficient (FDA, July 2026).

What did the published human studies of BPC-157 record about side effects?

The FDA's review lists five small human studies of BPC-157, of 2 to 53 people each and with limited safety reporting, and no serious adverse event appears to have been reported in any of them (FDA, July 2026). In a 2021 retrospective chart review of 17 people with knee pain, with no control group, the authors wrote that no adverse events were noted (Lee and Padgett, Alternative Therapies in Health and Medicine, 2021, as quoted by the FDA). In a 2024 pilot of 12 women with interstitial cystitis, a bladder-pain condition, with no control group, no one dropped out and no adverse events were reported (Lee et al., 2024). In a 2025 pilot of two adults who had used BPC-157 before, which cannot show safety, the authors reported no measurable effects on heart, liver, kidney, thyroid or blood-glucose markers (Lee and Burgess, 2025). The table below lists each study with its limits.

Read those lines with a cold eye. The knee study looked backwards at clinic charts and phoned patients six months to a year later, so anything forgotten went unrecorded (Lee and Padgett, 2021). The bladder pilot had no control group, so nothing in it can be set against placebo (Lee et al., 2024). The 2025 pilot had two participants, both of whom had used BPC-157 before the trial began (Lee and Burgess, 2025).

All three papers share a lead author, Lee E, and all were run in Florida clinics with BPC-157 made by United States compounding pharmacies (FDA, July 2026). Independent replication would carry more weight, and none was found for this page.

What does the FDA say about BPC-157 safety?

The FDA says it lacks enough information to know whether BPC-157 would cause harm in humans. Its page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, lists BPC-157 among substances nominated and then withdrawn, with a warning about immunogenicity (an unwanted immune reaction) and peptide-related impurities (FDA, April 2026). In its July 2026 briefing document, FDA staff proposed not adding BPC-157 to the list of substances pharmacies may compound, citing missing safety data, immunogenicity risk and too little evidence for ulcerative colitis (FDA, July 2026).

An advisory committee then met on 23 July 2026. The Regulatory Affairs Professionals Society reported that it "voted 8-6 with one abstention" to recommend that two peptides, BPC-157 for ulcerative colitis and KPV, be added to the 503A bulks list (RAPS, 23 July 2026). The FDA's meeting page carries no vote result and says advisory committees make non-binding recommendations, and the FDA's briefing states that it will not issue a final determination until the committee's input has been considered and all reviews are finalised (FDA, July 2026). A vote on a list is a decision about pharmacy compounding. It is not an approval, and the FDA's briefing records that a globalEDGE search found no approved product containing BPC-157 in any country (FDA, July 2026).

The FDA also named what the human record lacks. Its search found no human studies of the routes nominated for compounding, and it saw no information on how the body absorbs the peptide by those routes (FDA, July 2026).

What adverse events have been reported to regulators for BPC-157?

Three adverse-event reports for BPC-157 reached the FDA's reporting system, FAERS, through 4 December 2025, and the FDA could not say that BPC-157 caused any of them (FDA, July 2026). In the FDA's summary, a 55-year-old woman reported nine days of redness and swelling where a product was given, while also using a thymosin product, in a voluntary report that does not establish cause (FDA, July 2026). A 28-year-old man reported shortness of breath that led to an emergency visit, with no further detail, in a voluntary report that does not establish cause (FDA, July 2026). A 40-year-old woman reported darkened skin and gums that returned when she tried a BPC-157 and TB-500 product again, in a voluntary report that does not establish cause (FDA, July 2026).

Reports like these are signals, not measurements. People file them voluntarily, and the FDA says it cannot reach firm conclusions about safety from FAERS alone (FDA, July 2026). Its food-complaint search through 3 December 2025 retrieved three cases involving multi-ingredient BPC-157 supplements, voluntary reports that cannot establish which ingredient caused a reaction (FDA, July 2026). The FDA's own PubMed and Embase search identified no published BPC-157 case reports in the literature it searched (FDA, July 2026).

Clinical reviews say much the same. A 2025 systematic review of 36 studies in HSS Journal, of which 35 were preclinical, found no clinical safety data and warned that adverse effects remain possible because of unregulated manufacturing, contamination or unknown clinical safety (Vasireddi et al., HSS Journal, 2025).

What side effects has the TGA recorded for unapproved peptide products?

The TGA has recorded adverse events and other concerns for unapproved peptide products as a group, and it has not tied them to BPC-157 alone. Its 13 April 2026 advisory lists severe allergic reactions needing adrenaline and hospital care, a body-wide inflammatory reaction, widespread itching, palpitations, insomnia, blurred vision, extreme tiredness, joint pain and tendon injuries such as Achilles tendinitis, as reports for products whose contents the TGA could not verify, with no case count in the advisory and no BPC-157-specific attribution (TGA, 13 April 2026). A joint statement from the TGA and the Chief Medical Officer on 19 June 2026 listed liver damage for unapproved peptides as a group, without case counts or BPC-157-specific attribution (TGA and CMO, 19 June 2026).

The advisory names BPC-157 as one example beside GHK-Cu, TB-500, retatrutide and CJC-1295. The reports concern products whose contents the TGA could not verify, so its text does not say whether any reaction came from the peptide, a contaminant or another ingredient. The TGA says information on how these products work in the body and what side effects they may cause remains unknown (TGA, 13 April 2026).

How Australian law treats BPC-157 has its own guide, BPC-157 and the Poisons Standard, which this page does not repeat.

What is known about the side effects of BPC-157 tablets and other oral forms?

The FDA's July 2026 review identified no human study of oral BPC-157 reporting side effects, and the one registered oral trial, NCT02637284, has no posted results (FDA, July 2026). That Phase 1 trial listed 42 planned healthy volunteers aged 18 to 35, with adverse events as the primary outcome, and its record was last updated in December 2015 (ClinicalTrials.gov). Its status is listed as unknown, and the FDA review says it was unable to find an associated published study.

The FDA review reports that BPC-157 resisted breakdown in human gastric juice in vitro (in a test tube), with no sample count in its summary, a laboratory finding that does not establish human absorption or safety (FDA, July 2026). A 2026 narrative review describes the human pharmacokinetic profile as critically undercharacterised (Mateescu et al., Pharmaceutics, 2026).

The FDA judged the immune-reaction risk of an oral peptide likely to be low, while staying concerned about peptide-related impurities in any product form (FDA, July 2026).

Do BPC-157 side effects differ in women or men, or in pregnancy?

The FDA briefing and PubMed records searched for this page on 14 October 2026 did not find a study that analysed BPC-157 side effects by sex, or one in pregnant people. Women made up the whole 12-person bladder pilot, which had no control group and reported no adverse events (Lee et al., 2024), and two of the three FDA adverse-event reports came from women (FDA, July 2026). The only pregnancy-related data found are from rats: in a 2020 study, the FDA's summary says BPC-157 had no effect on numbers of live fetuses, fetal weight or malformations, a result in rats whose group size the FDA summary does not give, that does not carry over to people and did not cover a full reproductive cycle (Xu et al., Regulatory Toxicology and Pharmacology, 2020, as summarised by the FDA in July 2026).

A rat result does not carry over to pregnant women. The FDA noted that the 2020 study did not follow a full reproductive cycle, from conception through the next generation (FDA, July 2026). The PubMed search run for this page on 14 October 2026, for BPC-157 together with pregnancy terms in titles or abstracts, returned no records.

Men are in the same position. The 2025 pilot included one man and one woman, and no published report found for this page separates results by sex (Lee and Burgess, 2025).

Does BPC-157 cause liver damage or liver problems?

In the FDA's list of five small human studies, of 2 to 53 people each, no liver damage from BPC-157 was reported, and none was large enough to rule it out (FDA, July 2026). In a 2025 pilot of two adults, liver markers did not change measurably, in a two-person pilot that cannot show safety (Lee and Burgess, 2025). Across 28-day tests in rats and dogs, whose group sizes the FDA summary and the paper's abstract do not give, FDA reviewers flagged liver-related signals: higher ALT, a liver enzyme, plus higher glucose and triglycerides, findings in animals that do not describe humans (FDA, July 2026, summarising Xu et al., 2020). A rat study went the opposite way, reporting smaller liver lesions after a toxic drug challenge, in rats whose group size the abstract does not give, an animal finding that does not establish a human result (Ilic et al., Life Sciences, 2011). The TGA lists liver damage among harms linked to unapproved peptides in general (TGA and CMO, 19 June 2026).

Mixed signals are normal at this stage of research. The same 28-day paper that the FDA reads as raising flags described BPC-157 as well tolerated overall in mice, rats, rabbits and dogs, with group sizes not given in its abstract, an animal finding that does not describe humans (Xu et al., 2020), which is how two careful readers can look at one dataset and disagree. A longer, guideline-compliant toxicity study could help investigate the discrepancy, and a 2026 review notes that none has been reported in a form regulators would accept (Mateescu et al., Pharmaceutics, 2026).

Can BPC-157 affect the heart, blood pressure or cholesterol?

The sources searched for this page found human data on BPC-157 and the heart only in a two-adult pilot and in human artery tissue studied in a lab bath, and a PubMed search run for this page on 14 October 2026 for BPC-157 together with cholesterol in titles or abstracts returned no records. In a 2025 pilot of two adults, the authors reported no clinically significant change in blood pressure, heart rate or heart-related blood tests, and a two-person pilot cannot show safety (Lee and Burgess, 2025, as tabulated by the FDA in July 2026). In rats, with group sizes not given in the abstract, BPC-157 left normal blood pressure alone but altered the pressure rise caused by the drug L-NAME, a finding in rats that does not describe humans (Sikirić et al., European Journal of Pharmacology, 1997). In rings of human internal mammary artery taken from 12 bypass operations, it relaxed the vessel wall in a lab bath, a tissue finding that does not show an effect in a living person (Yildirim et al., Journal of Clinical Medicine, 2026).

A dish of artery tissue is a long way from a beating heart. The 2026 paper itself says further molecular and whole-body studies are needed to clarify clinical relevance (Yildirim et al., 2026). On cholesterol, the PubMed search described above returned no records, and the only lipid hint found for this page is the triglyceride rise that FDA reviewers noted in the 28-day rat and dog studies, whose group sizes the FDA summary does not give, a finding in animals that does not describe humans (FDA, July 2026).

Can BPC-157 cause blood clots or change how blood clots?

The FDA briefing and PubMed records checked for this page on 14 October 2026 include no human study that tested whether BPC-157 changes clotting. In 28-day studies, the FDA read a shorter clotting time (aPTT, a lab measure of clotting speed) in rats and a longer one in dogs as signs of altered clotting properties, findings in animals, with group sizes not given in the FDA summary, that do not describe humans (FDA, July 2026, from Xu et al., 2020). A 2012 rat study from the Zagreb group that produced most of the preclinical work found less bleeding and smaller platelet falls in rats given heparin, warfarin or aspirin, with group sizes not given in its abstract and no human study behind the finding (Stupnisek et al., Thrombosis Research, 2012). A 2019 study from the same group reported that BPC-157 counteracted the aggregation-blocking effect of aspirin, clopidogrel and cilostazol in tests on blood from rats, with group sizes not given in its abstract and no human study behind it (Konosic et al., Oxidative Medicine and Cellular Longevity, 2019).

A 2026 review states that formal drug-interaction studies, in the lab and in living animals, are still needed (Mateescu et al., Pharmaceutics, 2026).

Those animal findings do not establish clot risk in people. The FDA's list of five small human studies of 2 to 53 people each, with limited safety reporting, records that no serious adverse event appears to have been reported, and its search identified no published case report (FDA, July 2026).

Does BPC-157 grow blood vessels, and does that raise cancer risk?

Whether BPC-157 changes cancer risk in people is unknown. Hsieh and colleagues found more vessels in a chick-membrane assay, more tube formation in cultured human endothelial cells, faster blood-flow recovery in rat hind limbs with poor supply, and higher VEGFR2, a receptor that signals vessel growth, in laboratory and rat models, with sample sizes not given in the abstract, that do not show an effect in people (Hsieh et al., Journal of Molecular Medicine, 2017). The FDA review did not identify carcinogenicity studies of BPC-157, which are the animal studies that test cancer risk (FDA, July 2026), and a 2026 review calls this a major theoretical safety uncertainty (Mateescu et al., Pharmaceutics, 2026).

People who ask whether BPC-157 makes you vascular usually mean visible veins. The FDA briefing and PubMed records checked on 14 October 2026 did not identify a BPC-157 study measuring vein visibility or body composition. The vessel studies above counted tiny vessels in tissue sections and cultured cells, not veins you can see.

The cancer question is disputed in print. A 2025 literature review raised concerns about vessel-growth signalling, and a subsequent comment challenged that interpretation; these are opposing readings of preclinical evidence, not human cancer-risk measurements (Józwiak et al., Pharmaceuticals, 2025; Sikirić et al., Pharmaceuticals, 2025).

What do studies show about BPC-157 and joint pain, meniscus tears, cartilage or a bulging disc?

The only human data on BPC-157 and joints found for this page are a 2021 retrospective review of 17 people with knee pain, in which 14 of the 16 reached by phone reported relief, rated by phone recall without a validated scale, imaging or control group (Lee and Padgett, 2021). A PubMed search on 14 October 2026 found no BPC-157 paper reporting a meniscus, cartilage or intervertebral disc result in its title or abstract. A 2026 scoping review of six peptides, searched in PubMed, described the human clinical studies as limited to a handful of investigations, most lacking robust controls or rigorous study designs, and the human data as heterogeneous (Tewari et al., American Journal of Sports Medicine, 2026).

The 2021 authors called for follow-up MRI scans, and their stated potential for tissue repair is a hope, not a result. An uncontrolled report like theirs cannot separate an effect of treatment from other explanations, such as placebo response.

In the same 14 October 2026 search, the words meniscus and cartilage appeared in only a handful of BPC-157 records, and the matches were reviews and the knee report's own list of possible causes of knee pain. A bulging disc returned no records.

Evidence limits

What is still unknown about BPC-157 safety?

Most of the preclinical work comes from one academic group in Zagreb, and the 2026 Pharmaceutics review notes that the first independent pharmacokinetic data came from a group in Xi'an, China (Mateescu et al., 2026). The 2025 HSS Journal review found 36 qualifying studies, of which 35 were preclinical and one was clinical (Vasireddi et al., 2025). Independent confirmation is the missing ingredient behind almost every question above.

Is research-use BPC-157 the material these studies tested?

No. The Florida pilots above used BPC-157 made by United States compounding pharmacies, and the 2002 to 2005 meeting abstracts used a developer's product coded PL 14736 (FDA, July 2026), while the animal studies used laboratory peptide under study conditions. Research-use reference material is a laboratory compound. It is not a medicine, is not a substitute for one, and is not for human or animal use. The FDA found BPC-157 not well characterised from a physicochemical perspective, so a name on a label does not tell a reader what any one study measured (FDA, July 2026).

The catalogue lists BPC-157 reference material as laboratory stock. A listing is a catalogue record, not evidence about any study. Reading the paperwork that comes with a batch is its own skill, and the quality and verification hub explains what a certificate can and cannot show.